1.44
+0.01(+0.70%)
Currency In USD
| Previous Close | 1.43 |
| Open | 1.49 |
| Day High | 1.49 |
| Day Low | 1.37 |
| 52-Week High | 179.35 |
| 52-Week Low | 1.37 |
| Volume | 41,820 |
| Average Volume | 50,519 |
| Market Cap | 821,922 |
| PE | 0 |
| EPS | 1,229.73 |
| Moving Average 50 Days | 2.67 |
| Moving Average 200 Days | 4.39 |
| Change | 0.01 |
If you invested $1000 in Onconetix, Inc. (ONCO) since IPO date, it would be worth $0.01 as of December 30, 2025 at a share price of $1.44. Whereas If you bought $1000 worth of Onconetix, Inc. (ONCO) shares 1 year ago, it would be worth $2.17 as of December 30, 2025 at a share price of $1.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
GlobeNewswire Inc.
Sep 26, 2025 12:30 PM GMT
CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
GlobeNewswire Inc.
Sep 26, 2025 12:15 PM GMT
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in op
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s heal